Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Initial Results froma Phase 2 Trial of Motesanib Diphosphate (AMG 706) in Patients (pts) with Medullary Thyroid Carcinoma (MTC)

Schlumberger M, Elisei R, Sherman S, Bastholt L, Wirth L, Martins R, Licitra L, Jarzab B, Pacini F, Daumerie C, Droz JP, Shi Y, Sun Y-N, Stepan D. Initial Results froma Phase 2 Trial of Motesanib Diphosphate (AMG 706) in Patients (pts) with Medullary Thyroid Carcinoma (MTC). ENDO Society 2007. 2007; Abstr #852315.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.